The two California startups will aggregate genomic and phenotypic data, including social determinants of health, to support and manage decentralized clinical trials.
The company also said that it had received EUA from the US Food and Drug Administration for a non-prescription version of its COVID-19 sample collection kit.
Bio-Techne's CEO said the coverage decision will expand access to its EPI test and enable additional men to better decide whether to proceed with a prostate biopsy.
Hologic said that the transaction further strengthens its molecular diagnostics business by expanding its international capabilities, among other benefits.
The firm said it is drawing up plans for its business in a post-pandemic world, planning the introduction of new testing panels and enhancing its respiratory panel.
